Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment
Copyright © 2021 Elsevier B.V. All rights reserved..
Alloantibodies, in particular immunoglobulin G (allo-IgG), confer a rejection advantage to tumors sharing the same major histocompatibility complex (MHC) in mice. However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation. Here, we developed high titer allo-IgG by multiple rounds of immunization with allogenic B16 melanoma cells, which allows for the strong binding with B16 cells. We demonstrate that B16 cells incubated with these allo-IgG (referred to as allo-IgG-B16) become highly immunogenic, which release tumor antigens that are efficiently presented by classic DCs in lymph nodes (LNs). Injection of allo-IgG-B16 turns the tumor into an immune hot one and even elicits a systemic antitumor response when used together with 5-fluorouracil (5-FU). This systemic response is tumor-specific and relies on the critical site - LNs. Our findings provide a rationale for the use of allo-IgG in cancer treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:503 |
---|---|
Enthalten in: |
Cancer letters - 503(2021) vom: 10. Apr., Seite 151-162 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dang, Nana [VerfasserIn] |
---|
Links: |
---|
Themen: |
CD8(+) T cells |
---|
Anmerkungen: |
Date Completed 05.08.2021 Date Revised 05.08.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.canlet.2021.01.027 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM321057961 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM321057961 | ||
003 | DE-627 | ||
005 | 20231225175013.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.canlet.2021.01.027 |2 doi | |
028 | 5 | 2 | |a pubmed24n1070.xml |
035 | |a (DE-627)NLM321057961 | ||
035 | |a (NLM)33545224 | ||
035 | |a (PII)S0304-3835(21)00051-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dang, Nana |e verfasserin |4 aut | |
245 | 1 | 0 | |a Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.08.2021 | ||
500 | |a Date Revised 05.08.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
520 | |a Alloantibodies, in particular immunoglobulin G (allo-IgG), confer a rejection advantage to tumors sharing the same major histocompatibility complex (MHC) in mice. However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation. Here, we developed high titer allo-IgG by multiple rounds of immunization with allogenic B16 melanoma cells, which allows for the strong binding with B16 cells. We demonstrate that B16 cells incubated with these allo-IgG (referred to as allo-IgG-B16) become highly immunogenic, which release tumor antigens that are efficiently presented by classic DCs in lymph nodes (LNs). Injection of allo-IgG-B16 turns the tumor into an immune hot one and even elicits a systemic antitumor response when used together with 5-fluorouracil (5-FU). This systemic response is tumor-specific and relies on the critical site - LNs. Our findings provide a rationale for the use of allo-IgG in cancer treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a CD8(+) T cells | |
650 | 4 | |a Dendritic cells | |
650 | 4 | |a Lymph nodes | |
650 | 4 | |a Regulatory T cells | |
650 | 4 | |a Tumor antigens | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
650 | 7 | |a Isoantibodies |2 NLM | |
650 | 7 | |a Fluorouracil |2 NLM | |
650 | 7 | |a U3P01618RT |2 NLM | |
700 | 1 | |a Lin, Yuan |e verfasserin |4 aut | |
700 | 1 | |a Waer, Mark |e verfasserin |4 aut | |
700 | 1 | |a Sprangers, Ben |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 503(2021) vom: 10. Apr., Seite 151-162 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
773 | 1 | 8 | |g volume:503 |g year:2021 |g day:10 |g month:04 |g pages:151-162 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2021.01.027 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 503 |j 2021 |b 10 |c 04 |h 151-162 |